Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait

J Cytol. 2016 Jan-Mar;33(1):1-6. doi: 10.4103/0970-9371.175476.

Abstract

Context: Nonsmall cell lung carcinoma (NSCLC) is the most frequently diagnosed form of lung cancer in Kuwait. NSCLC samples from Kuwait have never been screened for epidermal growth factor receptor (EGFR) gene aberration, which is known to affect treatment options.

Aims: This study investigated the feasibility of using fine-needle aspiration (FNA) material for mutational screening, and whether common EGFR mutations are present in NSCLC samples from Kuwait.

Settings and design: Eighteen NSCLC samples from five Kuwaitis and 13 non-Kuwaitis were included in this study.

Materials and methods: DNA was extracted from FNA cell blocks and screened for EGFR gene mutations using peptide nucleic acid (PNA)-clamp assay, and EGFR gene amplification using fluorescent in situ hybridization (EGFR-FISH). EGFR protein expression was assessed using immunohistochemistry.

Results: Five EGFR mutations were detected in five non-Kuwaiti NSCLC patients (27.8%). EGFR gene amplification was evident in 10 samples (55.5%) by direct amplification or under the influence of chromosomal polysomy. Four samples had EGFR mutations and EGFR gene amplification, out of which only one sample had coexisting EGFR overexpression.

Conclusions: Given the evidence of EGFR gene alterations occurring in NSCLC patients in Kuwait, there is a need to incorporate EGFR gene mutational screen for NSCLC patients to implement its consequent use in patient treatment.

Keywords: Epidermal growth factor receptor (EGFR); fine-needle aspiration (FNA); lung adenocarcinoma; mutational screen; nonsmall cell lung carcinoma (NSCLC).